EMCDDA–Europol Joint Report on a new psychoactive substance: MDPV (3,4-methylenedioxypyrovalerone)

In accordance with Article 5 of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances

About this series
EMCDDA–Europol Joint Report publications examine the detailed information provided by the EU Member States on individual new psychoactive substances. Information is collected from the Reitox network, the Europol national units and the national competent authorities of the European Medicines Agency. Each Joint Report serves as the basis upon which the decision to conduct a risk assessment of the new psychoactive substance is taken. It is part of the three-step procedure involving information exchange, risk assessment and decision-making in the framework of the Council Decision 2005/387/JHA.
Contents

3  1. Introduction
3  2. Information collection process
4  3. Information required by Article 5.2 of the Decision
4   3.1 Chemical and physical description, including the names under which the new psychoactive substance is known — Article 5.2(a) of the Decision
5   3.2 Information on the frequency, circumstances and/or quantities in which a new psychoactive substance is encountered, and information on the means and methods of manufacture of the new psychoactive substance — Article 5.2(b) of the Decision
5      3.2.1 Information provided to Europol
8      3.2.2 Information provided to the EMCDDA
9   3.3 Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance — Article 5.2(c) of the Decision
9   3.4 A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Decision
10      3.4.1 First indication of health risks
13      3.4.2 Characteristics of users
15   3.5 Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system — Article 5.2(e) of the Decision
16   3.6 The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol — Article 5.2(f) of the Decision
16   3.7 Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State — Article 5.2(g) of the Decision
17      3.8 Further information — Article 5.2(h) of the Decision
18      3.8.1 The chemical precursors that are known to have been used for the manufacture of the substance
18      3.8.2 The mode and scope of the established or expected use of the new substance
18      3.8.3 Other use of the new psychoactive substance and the extent of such use, the risks associated with this use of the new psychoactive substance, including the health and social risks
18  4. Information from the EMA as requested by Article 5.3 of the Decision
18      4.1 Marketing authorisation
18      4.2 Application for a marketing authorisation
18      4.3 Suspended marketing authorisation
18  5. Conclusions
19  References
21  Annexes

Acknowledgements

The EMCDDA would like to thank the following for their contribution in producing this publication:

- the Early-warning system (EWS) correspondents of the Reitox national focal points (NFPs) and experts from their national EWS networks;
- the Europol national units (ENUs) and Europol Project Synergy;
- the national competent authorities responsible for human and veterinary medicinal products in the Member States, Norway and Iceland;
- the European Medicines Agency (EMA) and the European Commission;
- the World Health Organization;
- EMCDDA staff: Brendan Hughes, Isabelle Giraudon, Athanasios Stamos, Marta Rychert and Katarzyna Nationiewska.

Project team: Andrew Cunningham, Michael Evans-Brown, Ana Gallegos, Roumen Sedefov, Anabela Almeida (EMCDDA) and Daniel Dudek (Europol).
1. Introduction

Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the ‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by a majority of its members, consider that the information provided by the Member State on a new psychoactive substance merits the collection of further information, this information shall be collated and presented by Europol and the EMCDDA in the form of a Joint Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be submitted to the Council, the European Medicines Agency (EMA) and the Commission.

At the end of September 2013, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol examined the available information on a new psychoactive substance 3,4-methylenedioxypyrovalerone, commonly known by the abbreviation ‘MDPV’, through a joint assessment based upon the following criteria:

1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.

The EMCDDA and Europol agreed that the information collected on MDPV satisfied criteria 1, 2, 3, 4 and 6. The two organisations therefore concluded that sufficient information had been accumulated to merit the production of a Joint Report on MDPV as stipulated by Article 5.1 of the Decision.

Europol asked the Europol National Units to provide information on:

- the level of production of MDPV in their country;
- the level of distribution of MDPV in their country;
- the level of trafficking of MDPV in their country, both for internal, transit or export purposes;
- the number of seizures of MDPV in their country, the total amount of the seizures, country of origin, details on the physical forms (including photos);
- the role of organised crime, or criminal groups, in the production, distribution and trafficking of MDPV in their country; and,
- any known aspect of violence and/or money laundering relating to the production and trafficking of MDPV.

Europol received responses from 15 Member States.

According to Article 5.3 of the Decision, the EMA asked the national competent authorities responsible for human and veterinary medicinal products in the Member States as well as in Norway and Iceland to provide information on whether:

- the new psychoactive substance MDPV has obtained a marketing authorisation;
- the new psychoactive substance MDPV is the subject of an application for a marketing authorisation; and,
- a marketing authorisation that had been granted in respect of the new psychoactive substance MDPV has been suspended.

Twenty-five Member States (2), Norway and Iceland replied to the EMA’s request. The EMA also provided information as relevant to the central authorisation procedure.

Furthermore, in anticipation of Article 7.3 of the Decision in relation to the manufacturing of medicinal products in the European Union, the EMA also requested whether the new psychoactive substance MDPV is used to manufacture a medicinal product:

- which has been granted a marketing authorisation;
- for which an application has been made for a marketing authorisation; and,
- for which a marketing authorisation has been suspended by a competent authority.


(2) Austria, Belgium, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.
Twenty-four Member States (3), Norway and Iceland replied to the EMA’s request. The EMA also provided information as relevant to the central authorisation procedure.

The EMCDDA collected data through:

1. a structured questionnaire from the Reitox national focal points. The EMCDDA received replies from 28 Member States as well as Norway and Turkey;
2. data previously provided to the EU early-warning system (EWS) in EMCDDA–Europol Reporting Forms, EWS Progress and Final Reports;
3. a specific information request to the World Health Organization on whether or not MDPV is under assessment by the United Nations system (see section 3.5); and,
4. a structured search of the scientific literature and of relevant Internet sites.

Thus, information included in sections 3.2.1 and 3.3 of the Joint Report was provided by Europol, while the EMCDDA provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included in sections 3.8.3 (in part), 4.1, 4.2 and 4.3 was provided by the EMA. The conclusion of the Joint Report were prepared and agreed by the two organisations responsible — the EMCDDA and Europol. Further details of the seizures and collected samples (including images where available) reported to the EMCDDA are provided in Annex 1. The details of deaths associated with MDPV that have been reported to the EMCDDA are provided in Annex 2.

3. Information required by Article 5.2 of the Decision

The order and titles of subsections 3.1 to 3.8 and section 4 below are as they appear in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Decision; all sections are cross-referenced with those set down in the Decision.

3.1. Chemical and physical description, including the names under which the new psychoactive substance is known — Article 5.2(a) of the Decision

Chemical description and names

MDPV is a synthetic derivative of the naturally occurring substance cathinone, one of the psychoactive principles in khat (*Catha edulis* Forsk). All monitored synthetic cathinone derivatives are either $N$-alkylated or the nitrogen atom is part of a pyrrolidine ring, which is the case with MDPV. Most of the cathinone derivatives are also ring-substituted and MDPV contains the 3,4-methylenedioxy substitution pattern on the phenyl ring that is observed in other illicit drugs such as MDMA (3,4-methylenedioxymethamphetamine).

Pyrrolidine derivatives, such as MDPV, can be regarded as a subset of cathinone derivatives sharing the same structural skeleton as pyrovalerone (Figure 1). Other examples in this group are 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone (α-PVP) and 4-methyl-α-pyrrolidinobutyrophenone (MPBP).

MDPV is the common name for 3,4-methylenedioxyppyrovalerone. The systematic chemical name is: (RS)-1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl) pentan-1-one.

Additional chemical synonyms reported are:

- 1-(3,4-methylenedioxyphenyl)-2-pyrrolidinyl-pentan-1-one;
- 1-(3,4-methylenedioxy-phenyl)-2-pyrrolidin-1-yl-pentan-1-one;
- 1-(benzo[d][1,3]dioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one;
- 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one;
- 1-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;
- (RS)-[1-(3,4-metyleniidioksifenyyli)-2-(1-pyrrolidinyyli)-1-pentanoni] (Finnish).

Common names or codenames that have also been reported are: MDPK and metyleenidioksipyrovaleroni (Finnish).

The following street names have also been reported: MDPK, Magic, Super Coke, Peevee, New Ivory Wave, Kannibaldrogen, Apdam, Aakkoset (meaning alphabet in Finnish), Bath Salt, MP, MP4 and MP3.


(3) Austria, Belgium, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom.
The molecular structure, weight and monoisotopic mass of MDPV. The molecular structure for pyrovalerone is provided for comparison (* denotes the chiral centre).

**Chemical Abstract Service registry numbers (CAS RN)**

- 687603-66-3 free base
- 24622-62-6 hydrochloride salt
- 1388142-27-5 \( R \)-enantiomer base
- 1388142-28-6 \( S \)-enantiomer base
- 1246912-12-8 deuterated (\( D_8 \)) base
- 1246820-09-6 deuterated (\( D_8 \)) hydrochloride salt

The REACH registered substances database hosted by the European Chemicals Agency (ECHA) was searched using the CAS registry numbers listed above. The search returned no results.

**Physical description**

The free base form of MDPV has been described as a brown or yellow-green amorphous powder. The hydrochloride salt form is described as a white-tan crystalline hygroscopic powder with a melting point of 238–239°C.

Reports from seizures and collected samples have noted the presence of MDPV in: powders, powder-filled capsules, tablets, blotters (small paper doses for sublingual/buccal administration), liquids and vegetable material, and in residues on injecting equipment.

A more detailed description of MDPV seizures and collected samples encountered can be found in subsections 3.2.1 and 3.2.2 below.
route to third countries. The final destinations in these cases were: Italy (three cases), the Netherlands (three) and the United Kingdom (two). The seized MDPV destined for Italy ranged from 18 g to 510 g. On two occasions the substance was labelled as ‘ULTRAVIOLET AB’ (18 g and 510 g) and as ‘LITHOPHONE’ (100 g) on the other occasion. The MDPV ordered by consumers in the Netherlands was labelled as ‘SODIUM ALGINATE’, with the following quantities seized: 1 516 g, 1 521 g and 2 022 g. In one of the two cases when MDPV was destined for the United Kingdom market (which weighed 260 g in each case), the seized substance was labelled as ‘HETASTARCH’.

Bulgaria reported that customs authorities had reported 12 seizures of MDPV between July 2010 and March 2012. All seizures took place at Sofia Airport, and the substance had been sent to Bulgaria (in the majority of cases) from China, Spain, Portugal, the United Kingdom or the Netherlands. One case was reported that involved almost 5 000 small packages of MDPV being sent to Poland via Hungary. In these 12 seizures, 5 267 g and 300 tablets of MDPV were seized. In some cases MDPV powder was mixed with caffeine and lidocaine. MDPV tablets were pink in colour, with an elliptic shape and were packed in small packages (containing two tablets each) bearing the label: ‘DOVES RED’. MDPV in powder form was identified in small packages bearing different labels, for example, ‘IVORY WAVE’, ‘MOJO’, ‘FLOWER MAGIC POWDER’ and ‘LOAD’.

The Bulgarian authorities also reported that the Research Institute of Forensic Sciences and Criminology of the Ministry of the Interior has recorded 19 cases related to MDPV seizures. In some of these cases MDPV was destined for ‘smart shops’ located in nearby resorts on the Black Sea.

Croatia reported that MDPV was detected in 10 cases (14 g in total).

Estonia reported one seizure of MDPV (1.68 g), made by customs authorities in incoming mail from the United Kingdom. In this case, MDPV was mixed with alpha-PVP and pentedrone.

Finland reported that the number of seizures of MDPV had been higher a few years ago. Since the substance was classified as a controlled substance, the number had declined. According to data provided by Finland, there were eight incidents where MDPV was seized in powder form (63.5 g in total). There is also information that MDPV was identified in 11 blood samples (no further details were provided to Europol).

The German report to Europol mentioned two significant investigations during which seizures of MDPV were recorded. The first investigation was conducted between September 2011 and March 2013. It focused on the distribution of new psychoactive substances sold via the Internet as so-called ‘legal high’ products. During house searches made in March 2013, a total of 5 524 products containing new psychoactive substances (NPS) were seized. Moreover, during further mail confiscation another 3 999 NPS products were seized. Among these, the following products contained MDPV:

- 10 packages (1 g each) of the ‘bath salt’ labelled ‘Charlie Sheen’;
- 11 packages (1 g each) of the ‘bath salt’ labelled ‘Mojo’;
- 20 capsules (0.5 g each).

Further analysis revealed that more than 4 000 customers from Germany and other countries had used this now-disrupted network. The NPS products were ordered by wholesalers in Belgium, the Netherlands, the Czech Republic, Portugal and Belize.

The second German investigation involved online vendors who were involved in supplying MDPV and methoxetamine. In the framework of this investigation, 30 kg of different NPS products were seized. Amongst others, the following seizures of MDPV were identified:

- 4 packages (1 g each) of the ‘bath salt’ labelled ‘highway’;
- 6.29 g of a white powder labelled ‘4-FMP’;
- 13.58 g of a white powder labelled ‘MDPV’;
- 0.94 g of a white powder labelled ‘ECKO’, mixed with caffeine;
- a total of 90 g of a white powder with various labelling: ‘MDPV’, ‘methylone’, ‘4-FA’, with a purity of 73 %;
- a total of 2.568 g of a white powder with various labelling: ‘MDMAI’, ‘MPPP’, ‘Dimethocaine’, ‘Alpha PPP’, with a purity of 81 %;
- 1 g of a white powder labelled ‘Alpha-PPP’;
- 14 g of a white powder labelled ‘Alpha-PVP’;
- 30 g of a brown powder;
61 packages of the so-called ‘legal high’ product named ‘Brutal Powder’, mixed with caffeine and lidocaine;

10 grams of a white powder labelled ‘Dichloropan’;

28 g of a white powder labelled ‘Dimethocaine’;

24 g of green tablets, also containing caffeine;

78 g of green tablets ‘Benzo F’, also containing caffeine;

6 g of a white powder labelled ‘Synthacain’;

20 packages of the ‘bath salt’ named ‘Tony Montana’ (†) also containing caffeine and lidocaine.

Data provided by Germany concerning MDPV seizures were recorded from February 2011 and November 2013. There has been a huge number of seizures where MDPV was detected. Bearing in mind the number of seizures and level of distribution it can be concluded that the market for MDPV has been growing in recent years. German authorities assume that a high number of cases in relation to MDPV are unreported. In the majority of cases MDPV was identified in so-called ‘legal high’ products, with different labelling: ‘Mojo’, ‘Mitseez’, ‘Buzz Powder’, ‘Sweed’, ‘Ivy Wave’, ‘J White Powder Cleaner’, ‘Wakup’, ‘Yellow Submarine’, ‘XXX’, ‘Buty’, ‘Lionheart’, ‘Rush Hour’, ‘Let’s Play Crack Inside’, ‘Charlie Sheen’, ‘All Day, All Night – What the fuck’, ‘Highway’, ‘ECKO’, ‘Brutal Powder’, ‘Sextacy’, ‘Insomnia’ and ‘Ultra Charge’.

In most of these cases, MDPV was identified as main active ingredient mixed with other new psychoactive substances and/or adulterants such as: 4-MEC, flephedrone, butylone, MDPBP, TFMP, 3-FMC, MXE, 2C-E, para-fluoramphetamine, AM-2201, pentedrone and/or lidocaine, caffeine, starch, taurine, mannitol and benzocaine.

The seizures of MDPV ranged from 0.02 g (March 2012) to 1 kg (January 2013, made up of 2 x 500 g).

In Hungary the increase in availability, use and distribution of MDPV led the Ministry of Justice to propose an amendment to the Act on Drugs that then placed MDPV as a Class A drug. The Hungarian Europol Liaison Officer reported that MDPV was seized in tablet and powder form in 2009 and 2012 respectively. Seizures of MDPV tablets increased from 551 tablets in 2009 (six cases) to 8 522 tablets in 2012 (nine cases). Seizures of powder have increased from 133 g in 2010 to 9 579 g in 2010 and to 5 730 g in 2012. It has been noted that in 2013 the seizures of MDPV (both tablets and in powder form) fell significantly.

Italy reported a limited number of seizures of MDPV. Three seizures of MDPV (in total 307.6 g) were made in the provinces of Roma, Milano and Taranto (September–October 2013). Italian citizens were reported to be involved in these cases.

Lithuania reported four seizures of MDPV made in 2012, totalling 1.326 g.

In Poland, MDPV was seized as powder in quantities ranging from 0.11 g to 525 g. The largest seizure, in April 2013, when the substance was sent from China (ordered via www.sensearomatic.com) to Poland by shipping company FedEx.

Slovakia reported 24 cases where MDPV was seized as a powder (various colours). In a significant majority of cases, the substance was seized in small packages labelled with various names: ‘Long Play’ (eight cases); ‘Beep Beep’ (eight); ‘Speed Way’ (one); ‘Popeyes Sniff’ (one) and ‘LP’ (one). In almost all cases, MDPV was identified in a mixture with other new psychoactive substances, such as: 2-DPMP (†) and buphedrone (the majority), MABP, bk-MDMA and ethcathinone. Seizures of MDPV weighed between 0.218 g and 53.315 g.

The Slovakian Financial Administration reported a case focused on a ‘smart shop’ (Euphoria Shop Ltd) that distributed goods called ‘Aromatic herbs and imitations of spa salts’. The Forensic Institute revealed that the products contained MDPV. The goods were distributed via branches in six cities in Slovakia. In June 2012, during searches made in these branches and in the house of a suspect, a total amount of 19 562 packages containing MDPV were seized. In addition, five plastic bags with crystalline white powder (20 g, 80 g, 300 g, 800 g, 1 kg) and EUR 6 191 in cash were seized.

Slovakia also reported a seizure of 10 kg of MDPV powder by customs officers of the Airport Financial Administration (no other details provided).

According to Slovakian authorities, imports are ordered via the Internet and then delivered from China to Slovakia by mail order (DHL, TNT, FedEx, etc.).

No reports were received that indicated licit or illicit production of MDPV in any of these countries.

(†) Tony Montana is the name of Al Pacino’s character in the 1983 film Scarface, directed by Brian de Palma, which tells the story of a Cuban refugee who becomes a drug kingpin in the cocaine trade in Miami, USA.

(‡) 2-(Diphenylmethy)piperidine.
3.2.2. Information provided to the EMCDDA

According to reports to the EMCDDA, MDPV has been present on the EU drugs market since 2008 and subsequently a large volume of data has been collected during this period, of which a summary is presented below.

Twenty-seven Member States (all Member States with the exception of Luxembourg), Norway and Turkey reported detections of MDPV (6). Several of these products carry names that are associated with or similar to street names used for cocaine, amphetamine or ‘ecstasy’ (MDMA). Other substances found along with MDPV in the same preparation include a wide range of new psychoactive substances (predominantly cathinones, but also phenethylamines, piperazines, synthetic cannabinoid receptor agonists and a range of other substances), adulterants such as benzoic acid, lidocaine and caffeine, and in a smaller number of cases with substances that are internationally controlled or controlled at the EU level.

Where information has been provided, quantities of powder for single seizures ranged from 0.02 g (Germany and Poland) to 5 kg (Czech Republic). Hungary reported a seizure of 300 yellow tablets bearing a heart logo and a separate seizure of two white tablets bearing markings resembling the Louis Vuitton ‘LV’ logo (8). Norway reported a seizure of 98 purple tablets bearing a space ship/rocket logo. These tablet findings may suggest that MDPV is being sold as ‘ecstasy’. There were also unmarked tablets reported in a variety of colours, including white, grey, pink, reddish and green, although many of these were associated with ‘legal high’ products. A selection of images is provided in Annex 1.

More than 4 500 individual cases of MDPV powder have been reported, amounting to an excess of 200 kg of seized MDPV. The vast majority of these are small cases; however, 45 of them (reported by the Czech Republic, Finland, France, Hungary, Latvia, the Netherlands, Spain and Sweden) were in excess of 500 g, accounting for more than approximately one-third of the total weight of powder seized. In 2011, for example, customs authorities in Hungary made seven separate seizures of MDPV powder amounting to approximately 14.5 kg. Belgium, the Czech Republic, Germany and Lithuania provided information that MDPV seized by customs authorities had been sent from China. No other non-EU countries were identified in the reports, although two Member States reported the interception of packages sent from another Member State. Several countries reported MDPV in powders contained in ‘legal high’ products with names such as ‘Charlie Sheen’, ‘Synthacaine’ or ‘Speedway Pro’ (a full list of names is provided in Section 3.1 above).

There were over 500 cases involving MDPV tablets or capsules, containing approximately 30 000 tablets in total. Several countries reported tablets containing MDPV in branded ‘legal high’ products with names such as ‘Yellow Submarine’, ‘Doves Red’ and ‘Mind Candy’ (a full list of names is provided in Section 3.1 above).

MDPV has typically been seized in powder form (reported by all countries where MDPV was detected). Some countries also reported seizures of tablets or powder-filled capsules (Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden and the United Kingdom). Six countries (Denmark, Finland, France, Latvia, Sweden and the United Kingdom) have seized liquids containing MDPV. Finland and Poland each reported a single seizure of paper doses (also known as ‘blotters’), i.e. small pieces of paper impregnated with MDPV for sublingual/buccal administration. The Polish blotters (four in total) had an image of Bugs Bunny on them and also contained 2-DPMP, ethylphenidate and the nootropic substance piracetam. Hungary also reported two cases where MDPV was present as ‘powder on herb’ and Poland reported a seizure of a ‘legal high’ product labelled as ‘Greenway Speedway’, which contained vegetable material with MDPV present. Indeed, MDPV has often been found as an ingredient in so-called ‘legal high’ products, often in combination with other substances. Several countries have described these as ‘bath salts’, a term frequently used to describe ‘legal high’ products.

Seizures

Twenty-seven Member States (all Member States with the exception of Luxembourg), Norway and Turkey reported seizures (7) of MDPV to the EMCDDA. In excess of 5 500 seizures have been reported, with two countries reporting more than 1 000 seizures each: the United Kingdom (1 704) and Finland (1 340). A further four countries reported more than 100 seizures: Hungary (599), Poland (401), Ireland (242) and Spain (176).

MDPV has often been found as an ingredient in so-called ‘legal high’ products, often in combination with other substances. Several countries have described these as ‘bath salts’, a term frequently used to describe ‘legal high’ products.

Notes:

(6) ‘Detects’ is an all-encompassing term and may include seizures and/or collected and/or biological samples. Seizure means a substance available (seized) through law enforcement activities (police, customs, border guards, etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test purchases) for monitoring and research purposes. Biological samples are those collected from human body fluids (urine, blood, etc.) and/or specimens (tissues, hair, etc.).

(7) Many ‘seizures’ relate to individual case-level data. However, some data provided to the EMCDDA are aggregated at the country level. Some of the data from the United Kingdom are reported as ‘records’, where several records may come from the same case. Data is drawn from the Joint Report questionnaires and data provided in the bi-annual data gathering (EWS Progress and Final Reports) and from individual Reporting Forms submitted on an ad hoc basis.

(8) It is common to find markings on tablets sold as ‘ecstasy’ that copy those of popular cultural and iconic brands that are associated with quality. Louis Vuitton is a French fashion label.
Biological samples

Eleven countries reported detections of MDPV in biological samples, including:

- a total of 99 deaths: Finland (40 deaths), United Kingdom (32), Sweden (21), Poland (three), Austria (one), France (one) and Norway (one) – see section 3.4.1 and Annex 2 for further details;
- 107 analytically confirmed non-fatal intoxications: Sweden (99 cases), France (three), Italy (three) and Belgium (two);
- detections related to cases of suspicion of driving under the influence of drugs (Finland: 514 in the period 2009–13; Poland: one); driving under the influence of drugs and other crimes (Norway: nine; United Kingdom: one); drug testing (Poland: one); and unspecified detections in biological samples (Sweden: 842; Hungary: 387; United Kingdom: six; Norway: six).

Collected samples

In addition to the detections of MDPV in seizures and biological samples, ten Member States (Austria, Cyprus, Denmark, France, Ireland, Italy, the Netherlands, Poland, Slovakia and the United Kingdom) also reported collected samples.

In Austria 32 samples of powder were collected and analysed as part of the ‘pill’-testing project run by ‘ChEckiT!’ between 2010 and 2013. The samples were sold as mephedrone, cocaine, MDPV and speed. In two cases, amphetamine and caffeine or bk-MBDB (9) were also detected.

France reported nine samples of powder collected from different venues. Where quantitative information is available, the weight ranged from 0.1 g to 0.5 g. In two of the samples, alpha-PVP and pentedrone were also detected; in the other sample alpha-PVP and caffeine were detected. In one of the cases the sample was sold as cocaine.


In the Netherlands, the Drugs Information and Monitoring System (DIMS) detected MDPV in 27 samples (11 in 2010; nine in 2012; seven in 2013). Where information is provided, the samples were sold at consumer level as MDPV (one sample), cocaine (three), synthetic cocaine (two), ‘moji’ (one), 6-APB (10) (two), 5-APB (11) (one) and ‘meferon’ (two).

Poland reported 887 cases of branded products containing up to 500 mg of MDPV, mostly in powder form, as well as in tablets and capsules. Other substances detected in these samples were: other synthetic cathinones (naphyrone, methedrone, buphedrone, pentedrone methylone, 4-MEC, FMC, MDPBP, butylone, BMDP), phenethylamines (pFPP, fluoroamphetamine, 2C-E), synthetic cannabinoids (RCS-4, JWH-122, JWH-081), TFMPP, 5-HTP, creatine, lidocaine and caffeine.

Slovakia reported a total of 304 collected samples; some of them were offered through online shops (i.e. www.euphoriashop.sk, www.hypnotic.sk) under a variety of names including ‘Beep Beep’, ‘Long Play’, ‘Popeyes Sniff’, ‘Speed Way’, etc. Other substances often detected in the samples include the synthetic cathinones buphedrone, N-ethylcathinone and methylone, 2-DPMP and piracetam.

A small number of collected samples were reported by Cyprus, Denmark, Italy and the United Kingdom. In 2010 Cyprus reported MDPV in two samples of a product of 500 mg labelled ‘Ivory Wave’. Denmark reported three samples of powder in 2013. Italy reported a sample of 0.5 g of white powder purchased from the Internet and labelled ‘Ivory Wave’. On the label on the back of the package, ingredients listed were ‘water softening agents, Epsom salts, sodium bicarbonate, sodium chloride, amino acid blends, and naturally occurring trace elements and minerals’. No other substances in addition to MDPV were detected. The United Kingdom reported a sample of 33 g of MDPV powder purchased from an Internet retailer (www.chembay.co.uk) in December 2008.

Further details of these collected samples, including information on the product labels, are provided in Annex 1.

3.3. Information on the involvement of organised crime in the manufacture or trafficking of the new psychoactive substance — Article 5.2(c) of the Decision

According to German authorities there are no links to suggest the involvement of organised crime groups in the production, trafficking and/or distribution of MDPV. It should be borne in mind that easy access to substances (which can be in large amounts) within and outside the European Union via Internet shops indicates at least a certain level of organisation. In addition, organised crime groups’ interest and presence in the...
phenomenon of new psychoactive substances can be easily concluded from the substantial profits that can be obtained from this type of activity.

**Money laundering aspects**

No information was received on money laundering in connection with the production and/or trafficking of MDPV.

**Violence in connection with production, wholesale and distribution**

No information was received on incidents of violence in connection with the production, wholesale and/or trafficking of MDPV.

### 3.4. A first indication of the risks associated with the new psychoactive substance, including the health and social risks, and of the characteristics of users — Article 5.2(d) of the Decision

#### 3.4.1. First indication of health risks

Up to 107 non-fatal intoxications and 99 deaths, analytically confirmed to be associated with MDPV, were reported by Austria, Belgium, Finland, France, Italy, Poland, Sweden, the United Kingdom and Norway. Germany, Greece, Hungary, Ireland and Slovakia have also reported cases, which have not been described below due to their non-confirmed status.

**Non-fatal intoxications**

**Belgium**

Belgium reported two analytically confirmed, linked non-fatal intoxications in which the patients presented were stimulated, hypertensive and tachycardic. Traces of cocaine and amphetamines were also detected in urine samples (not quantified). They both reported visual and auditory hallucinations, severe psychosis and paranoia, and were aggressive. They were treated with antipsychotics and their status returned to normal after three to four days.

**France**

France reported three analytically confirmed non-fatal intoxication cases. In one case, the police brought a man in to the emergency department. In this case, delirium syndrome was reported, including hallucinations, as well as rhabdomyolysis, tachycardia, hypotension, agitation, logorrhoea and acute renal failure. The MDPV metabolite, pyrovalerone and cannabis were also detected in this case. In the second case, which was a ‘forced hospitalisation’, paranoid psychosis and aggression were noted. The symptoms reported were tachycardia, mydriasis, hypertension, agitation, profuse sweating, trembling, scarification and rhabdomyolysis. In this case, the route of administration was nasal and oral and the MDPV had been bought on the Internet. Methylone (4 400 ng/mL) was also detected in this case. In the third case, where the detection of MDPV was in a sample of hair, the patient had also bought MDPV via the Internet and the route of administration was nasal. Symptoms reported were mydriasis and paranoid psychosis. Cannabis and alcohol were also detected in this case.

**Italy**

Italy reported three analytically confirmed non-fatal intoxications. The first case was from August 2011 when a 20-year-old male was admitted to hospital very agitated with tachycardia (HR (12) 115 bpm). He reported having consumed cannabis, alcohol and three white capsules. MDPV was found in urine (14 mg/L) and butylone was also present (concentration not provided). The patient was treated with benzodiazepines and discharged two days later. The second case was from October 2012 and involved a 38-year-old male who presented at the emergency department with agitation, mild tachycardia (HR 105 bpm), distress and psychotic symptoms. He also reported visual and auditory hallucinations. He reported that he had taken ecstasy and synthetic drugs generally named as ‘mefre, crystal and energy’ by nasal insufflation. MDPV was detected in blood (12 mg/L) and urine (17 mg/L). Urine screening was negative for ketamine, atropine, scopolamine, levamisole, mephedrone, butylone, 4-MEC, methoxetamine, APB (13) (isomers), 4-FA (14), and MDAI (15). The third case also occurred in October 2012 and involved a 27-year-old male who presented at the emergency department. His father had found him in a state of agitation, confusion and anxiety. The patient reported having taken MDPV by intravenous injection for the last three to four days, together with benzodiazepines to counteract the excitatory effect of MDPV. The MDPV had been purchased from the Internet as a ‘bath salt’. Analysis of the patient’s urine revealed MDPV (55 µg/L), alprazolam (113.79 µg/L) and hydroxyalprazolam (103.59 µg/L). Three days after admission, the patient returned to the hospital for a second urine analyses, as requested by sanitary authorities. The patient reported continuing his use of MDPV and this was confirmed by the detection of MDPV in urine at a concentration of 35 µg/L. The analyses also found clor Diazepoxide.

(12) Heart rate.
(13) (Aminopropyl)benzofuran.
(14) 4-Fluoroamphetamine.
(15) 3,4-Methylenedioxymetidamine.
(13.03 µg/L), nordiazepam (61.55 µg/L), oxazepam (114.99 µg/L), diazepam (1.26 µg/L), temazepam (169.90 µg/L), alprazolam (10.43 µg/L) and alpha-hydroxylrazolam (13.45 µg/L).

Sweden

Sweden reported 459 non-fatal intoxications between 2007 and 2013 as follows: 2007 (one case), 2008 (four), 2009 (15), 2010 (47), 2011 (32), 2012 (194) and 2013 (166). Of these, between 86 and 99 cases are known to have been analytically confirmed (⁹). Two literature sources that describe a total of 99 non-fatal intoxications have been used for the purposes of describing the health risks. In the first report (Lindeman et al., 2013), cases of stimulant toxicity were studied from one hospital in Sweden covering April–May for three consecutive years (2010 to 2012). In April–May 2012 the number of patients with stimulant toxicity was 45, and 17 of these cases were examined toxicologically. Thirteen of these tested positive for MDPV and 12 were classified as chronic drug users, with >60 % noted to be hepatitis C virus (HCV) positive. The second study (Backberg et al., 2013) focused on the results of the STRIDa project, which monitors trends in acute poisonings with novel recreational drugs in Sweden. The study summarises the results for the first nine months in 2012 when MDPV was detected in 86 of 321 samples. In 17 cases the symptoms were severe (Poisoning Severity Score — PSS 3 (Persson et al, 1998)) and consisted of extreme agitation, psychosis, hyperthermia, tachycardia, hypertension, myocardial infarction, rhabdomyolysis and renal failure. A few patients needed therapy with sedatives for several days due to prolonged symptoms. It was noted by the authors that among the people that have come to medical attention, the incidence of severe poisonings (PSS 3) was highest for MDPV.

Deaths

There were 99 deaths associated with MDPV that were analytically confirmed. These were reported by Austria (one), Finland (40), France (one), Poland (three), Sweden (21), the United Kingdom (32) and Norway (one) (¹⁷).

Austria

Austria reported one death, which occurred in January 2012. The case involved a ‘young man’ who died from butylone (bk-MBDB) overdose in combination with MDPV, methylene and 4-MEC. No further details were provided.

Finland

Finland reported 40 deaths, which occurred between September 2009 and August 2013. The cases were all analytically confirmed, and where the concentration of MDPV was reported (20 cases) it ranged from 20 mg/mL to 4 800 mg/mL in blood; in all but one case, up to seven other substances were detected. In 14 cases, five or more substances were detected in addition to MDPV. The most frequently encountered other substances detected were diazepam (22 cases), amphetamine (14), buprenorphine (14), temazepam (nine), alprazolam (eight), ethanol (seven), morphine (three) and pregabalin (three). Causes of death reported were accidental poisoning (22 cases), suicidal poisoning (four), suicide resulting from crush injuries (two), suicide by hanging (two), suicide by carbon monoxide poisoning (one), unspecified intoxication (one), unspecified death and cirrhosis of liver (one), accidental injury to thoracic aorta (one), accidental death due to multiple rib fractures (one), infective myocarditis disease (one) and homicide (one). The cause of death had not yet been registered in three cases.

France

France reported one death, which occurred in October 2012. The cause of death was drowning. MDPV was present at a concentration of 106 µg/L (blood) and 760 µg/L (urine). Other drugs detected were: PVP (¹⁸) (blood 40 µg/L; urine 295 µg/L); pentedrone (blood 33 µg/L; urine 110 µg/L); hydroxyzine (blood 194 µg/L); nordiazepam (blood 47 µg/L); oxazepam (blood 8 µg/L); cannabinoic acid (blood 15.7 µg/L); and ethanol (blood 0.3 g/L). No further details were provided.

Poland

Poland reported three deaths associated with MDPV. The first death was in September 2010 and the reported cause of death was ‘metabolic dysfunction’ caused by MDPV. The concentration of MDPV determined in blood was 430 ng/mL and ephedrine was also detected at a concentration of 324 ng/mL. No further details were available. The second and third cases were reported from 2011. The second case involved a road traffic collision where one driver suffered severe injuries, resulting in his death. During the police investigation, packages of white powders, called ‘Ivory Speed’ and ‘Exclusive Dust’, were found (Adamowicz et al., 2013). MDPV was detected in blood at a concentration of 38 µg/mL, and buphedrone was also detected at a concentration of 127 ng/mL. The third case involved a man with a history of drug addiction who was found unresponsive after a night of partying. A witness reported that he had taken a product called ‘Speedway’ while at the party. The post-mortem

(⁹) There is a potential that there may be an overlap of some cases reported by Lindeman et al., 2013 and the cases reported by Backberg et al., 2013.

(¹⁷) Hungary reported two indirect deaths, which occurred in November 2011. No further details were provided and it is not known if these cases are analytically confirmed.

(¹⁸) Pyrrolidinovalerophenone.
examination showed emaciation, external hydrocephalus and atherosclerosis. The man also suffered from human immunodeficiency virus (HIV) infection (Adamowicz et al., 2013). MDPV was detected in blood at a concentration of 17 ng/mL, and clonazepam (1.2 ng/mL) and 7-aminoclonazepam (96 ng/mL) were also detected.

Sweden

Sweden reported 21 deaths: three in 2010, three in 2011, nine in 2012 and six in 2013. Brief comments were reported as follows: in 2010 the deaths were intoxications involving several substances (not further described); in 2011 none of the three deaths related only to MDPV; in 2012 there were several accidents, death by hanging and intoxications with several drugs (not further described); and in 2013 there was one car accident and intoxications with several drugs (not further described).

United Kingdom

The United Kingdom reported 32 deaths between January 2010 and an unspecified date in 2013 (11 in 2010; eight in 2011; 12 in 2012; one in 2013).

Where reported, the causes of death were noted to be hanging (seven cases), cardiac-related causes (19) (five), drug toxicity (four), drowning (two), carbon monoxide poisoning (two), asphyxia (one), multiple injuries (suicide) (two), hypovolemic shock due to laceration of left forearm associated with partial transection of cephalic vein (one). In the remaining cases the cause was either unascertained or not specified. In the cases of drug toxicity, MDPV was normally present with other drugs. Where reported, the most common other substances present were mephedrone (nine cases), 4-fluoromethcathinone (seven), cocaine (four), amphetamine (four) and MDMA (three), although a range of other controlled drugs and medicines were also detected. MDPV was not the sole cause noted in any of the cases, and was specifically implicated as a contributory factor in nine of the cases.

Norway

Norway reported one death in 2012 in which MDPV was detected during the toxicological examination of blood. The cause of death in this case was not reported and no further information was provided.

Pharmacology and mode of action

Work by Baumann et al. (2013a) provides a systematic evaluation of the pharmacology and mode of action of MDPV using in vitro and in vivo studies in rodents (20). In vitro data shows that MDPV acts as a potent catecholamine-selective (dopamine and noradrenaline) transporter blocker (Table 1), sharing some similarities with the structurally related compound pyrovalerone. Compared to cocaine, MDPV is 50-fold more potent at DAT (dopamine transporter), 10-fold more potent at NET (norepinephrine transporter), and 10-fold less potent at SERT (serotonin transporter) (Baumann et al., 2013a). In addition, the data also showed that MDPV does not act as a transporter substrate. Consistent with the in vitro data, in vivo microdialysis studies in rats found that MDPV increased extracellular concentrations of dopamine in the nucleus accumbens and was 10-fold more potent than cocaine; while in vivo locomotor activity testing (stereotypy and forward locomotion) and assessment of cardiovascular parameters (heart rate and blood pressure) found that MDPV is at least 10-fold more potent than cocaine in inducing locomotor activation, tachycardia and hypertension. The authors concluded that the ‘potent blockade of dopamine uptake caused by MDPV predicts that the drug has a high risk for abuse, whereas the potent blockade of norepinephrine uptake portends dangerous cardiovascular stimulation’ (Baumann et al., 2013a).

Simmler et al. (2013), using a human in vitro model, assessed the blood–brain permeability of MDPV. They reported that MDPV exhibited particularly high blood–brain barrier permeability as compared to other synthetic cathinones (with the exception of mephedrone) as well as reference compounds such as MDMA and amphetamine. In addition, they reported that the data for MDPV was consistent with active transport across the blood–brain barrier. The authors concluded that the potency of MDPV at the DAT and NET and high blood–brain barrier permeability could ‘result in high sympathomimetic toxicity and risk of addiction in humans’.

No studies were identified that have examined the pharmacology and mode of action of MDPV in humans.

Meyer et al. (2010) and Strano-Rossi et al. (2010) provide data on the possible metabolites and metabolic pathways for MDPV in vitro using rat and/or human urine and human liver microsomes.

(20) Specifically: heart attack (one case), cardiac arrest (one), cardiac failure (one), coronary artery disease (one) and ischaemic heart disease (one).

(20) See also Gregg and Rawls (2013), Huang et al. (2012).
TABLE 1
Transporter-mediated inhibition of uptake and stimulation of release in rat brain synaptosomes. Values are given as nM ± S.E.M. for N=3–4 experiments per drug. E\textsubscript{max} \% refers to percentage of maximal release response. Key: ‘—’ indicate that compounds failed to elicit >30 \% of the maximal response and therefore compounds are considered inactive in the release assay. Modified from Baumann et al. (2013a, 2013b)

<table>
<thead>
<tr>
<th>Compound</th>
<th>DAT uptake IC\textsubscript{50} (nM ± S.E.M.)</th>
<th>NET uptake IC\textsubscript{50} (nM ± S.E.M.)</th>
<th>SERT uptake IC\textsubscript{50} (nM ± S.E.M.)</th>
<th>DAT release EC\textsubscript{50} (nM ± S.E.M.)</th>
<th>NET release EC\textsubscript{50} (nM ± S.E.M.)</th>
<th>SERT release EC\textsubscript{50} (nM ± S.E.M.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDPV</td>
<td>4.1 ± 0.5</td>
<td>26 ± 8</td>
<td>3349 ± 305</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Cocaine</td>
<td>211 ± 19</td>
<td>292 ± 34</td>
<td>313 ± 17</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Methylone</td>
<td>1232 ± 133</td>
<td>1031 ± 162</td>
<td>1017 ± 59</td>
<td>117 ± 12 [96 ± 1]</td>
<td>140 ± 17 [94 ± 2]</td>
<td>234 ± 35 [98 ± 2]</td>
</tr>
<tr>
<td>Amphetamine</td>
<td>93 ± 17</td>
<td>67 ± 16</td>
<td>3418 ± 314</td>
<td>5.8 ± 0.4 [102 ± 1]</td>
<td>6.6 ± 0.7 [92 ± 1]</td>
<td>698 ± 71 [97 ± 2]</td>
</tr>
</tbody>
</table>

Toxicology

See ‘Pharmacology and mode of action’ (above) for an overview of some of the in vitro and in vivo animal data that is relevant to the toxicity of MDPV in humans.

Simmler et al. (2013) examined the cytotoxicity of MDPV in vitro using a cell membrane integrity assay, which measures the release of adenylate kinase from damaged cells. MDPV did not show apparent cytotoxicity at concentrations of 10 µM and 100 µM after 4 hours of incubation at 37°C. No studies were identified that have examined the toxicity of MDPV in humans.

The clinical features of acute toxicity associated with MDPV use as reported by the Member States are provided in section 3.4.1 ‘Non-fatal intoxications’ and ‘Deaths’ and in Annex 2. These include a number of analytically confirmed cases. Case reports/series of intoxications where MDPV was analytical confirmed report similar findings (Spiller et al., 2011).

Methods for the toxicological screening of MDPV in urine have been reported by Strano-Rossi et al. (2010) and in blood by Marinetti and Antonides (2013).

Dependence and abuse potential

A review by Gregg and Rawls (2013) provides an overview of the in vivo animal behavioural pharmacology studies relevant to the possible abuse potential of MDPV in humans (21). They note that in rats the administration of MDPV both lowered intracranial self-stimulation thresholds and led to self-administration across multiple doses; while in a progressive-ratio model of reinforcement, higher doses of MDPV produced the highest breakpoints (Aarde et al., 2013; Watterson et al., 2012). In addition, dose-substitution studies suggested that MDPV possessed greater potency and efficacy than methamphetamine, with escalation studies showing that MDPV increases drug intake at similar doses to those observed with methamphetamine (Watterson et al., 2012). Finally they note that studies in mice undertaken by Fantegrossi et al. (2013) found that MDPV discriminates from saline and fully substitutes for MDMA and methamphetamine.

The findings reviewed by Gregg and Rawls (2013) are supported by the work of Baumann et al. (2013a), which is discussed in the section on ‘Pharmacology and mode of action’ (above). They note that, based on the ‘potent and efficacious actions of MDPV on extracellular dopamine and motor activity’ shown in their study, suggests that MDPV has a high potential for abuse. In addition, they suggest that, given that MDPV has a weak effect on SERT, this may further enhance the reinforcing effects of the drug, given that studies have shown that elevations in synaptic serotonin can dampen the stimulant effects mediated by dopamine (Baumann et al., 2011; Wee et al., 2005). No studies were identified that have examined the dependence and abuse potential of MDPV in humans.

3.4.2. Characteristics of users

The section below includes a discussion of the characteristics of users, which includes information from self-reported use from Internet drug discussion forums and related websites (hereafter ‘user websites’). As such it is important to note that it is not possible to confirm the specific substance(s) used, nor the purity, dose, etc. Analyses of products containing new

(21) See also Watterson et al. (2013).
psychoactive substances that are sold on the drug market have shown that the composition can differ between that claimed by the retailer, as well as over different geographical areas and time. Similar caveats apply to these types of information that have been provided in case reports/series unless biological and collected samples were taken and subjected to toxicological and forensic analysis. In addition, the information provided by patients in case reports/series, and that provided on user websites, should be regarded as illustrative only and not taken as representative of users of MDPV in general. Finally, information from seizures, collected samples and user websites suggest that MDPV has been commonly sold as a ‘legal’ replacement for cocaine, amphetamine or ‘ecstasy’ (MDMA).

There is also information to suggest that MDPV has been sold directly on the illicit drug market as cocaine, amphetamine and MDMA, as well as mephedrone. In these cases users may be unaware that they are consuming MDPV. Additional research is required in order to examine to what extent the characteristics of MDPV users reflect those who use other stimulant drugs.

**Route of administration, dose and drug regimens**

Information provided by the Member States, and from case reports/series and user websites, suggests that the routes of administration for MDPV were mainly nasal (insufflation/sniffing), oral (swallowing) or intravenous injection. Two countries reported that MDPV was detected in paper blotters and therefore buccal or sublingual administration may also occur. Furthermore, two countries reported the presence of MDPV in vegetable material, and this product would most probably be smoked. Information from user websites suggests that rectal administration may also be a route that is used.

Information from case reports/series and user websites suggests that a range of doses are used that may depend on the route of administration. The Erowid user website includes a range of tentative ‘common doses’ for three routes of administration: insufflation 5–11 mg; oral 8–15 mg; rectal 6–12 mg (Erowid, 2013a). One case report noted that MDPV produces psychoactive effects with as little as 3 mg to 5 mg, depending on its route of administration, and the average dose is approximately 5 mg to 20 mg. This report goes on to say that repeated dosing is common to avoid an unpleasant come-down, as is described with large single doses (Ross et al., 2012).

France also reported cases identified on the basis of interviews with patients. For one of these cases, the patient reported suffering malaise, tetany, language disorders and respiratory distress after taking MDPV by injection. Another patient suffered abnormal movements, trismus, profuse sweating, visual disorders, insomnia, anorexia, dysuria, vertigo and dysuria for 24 hours after he had injected the drug. He also reported having taken 4-MEC. Another patient suffered agitation, confusion and had attempted suicide after injecting the drug. He also reported taking MDMA and ‘cathinone’ as well. Other symptoms reported included reduced appetite and weight loss, insomnia, loss of focus, absences, paranoia, a sensation of cold and a sensation of electrical discharge in the heels by patients who had taken MDPV intranasally. The drug had been bought on the Internet. A range of other effects were also noted, such as insomnia, psychomotor agitation (experienced for three days by an injecting user); anxiety, intellectual stimulation, obsession to consume MDPV, withdrawal symptoms, fatigue, sleep disorder and pain at the site of injection; chest pain, accelerated heart rate and sensation of warmth (injecting user); agitation, facial erythrosis, dryness of the mucous and anxiety for five days for a patient with intranasal use. Two others reported sexual stimulation and increased sociability.

Two studies are available that report the injection of MDPV, although its injection is documented in other countries, such as France, Romania and Finland. In the first study, 183 clients of a needle exchange programme in Hungary agreed to report their drug using habits (Csák et al., 2013). This study found that during 2011 changes occurred in the nature of primary injected substances: amphetamine was cited as the primary injected substance by 45.9 % of the respondents and MDPV by 48.1 %. Almost half of the former amphetamine injectors had switched to MDPV (64 people, 45.1 %) as had 10 (41.7 %) of the former heroin injectors and 11 (78.6 %) of those using other substances (cocaine and mephedrone). The second study (Lindeman et al., 2013), also mentioned in Section 3.4.1, was initiated due to a sharp increase in the number of enquiries to the Swedish Poisons Information Centre regarding intoxications with MDPV. Of particular note is that, of the patients with confirmed or suspected MDPV consumption, 95 % were classified as chronic drug users and >60 % were reported as positive for HCV.

Information from user websites suggests that MDPV may be used on its own as well as in combination with other new psychoactive substances, controlled drugs and/or prescription medication (Erowid, 2013b; Drugs Forum, 2013). In most of the cases of non-fatal intoxications and deaths reported by the Member States, other new psychoactive substances and/or controlled drugs were detected in biological samples (Section 3.4.1 and Annex 2).

**Subjective effects**

No studies were identified that have examined the subjective effects of MDPV in humans; information is largely limited to that provided in case reports/series (see ‘non-fatal intoxications’ and section above) and self-reported experiences from user websites. Table 2 provides an overview of the self-reported duration of effects when MDPV is taken by the oral and insufflated routes as reported by Erowid (2013c).
Table 3 provides an overview of subjective effects of MDPV as reported by Erowid (2013c). In both cases the information was collated from users, research and other resources. No further details were provided on the methodology used to collate this information. Information provided in case reports and case series of non-fatal intoxications associated with MDPV appear to support some of these effects. The section on ‘non-fatal intoxications’, above, provides an overview of the other adverse effects reported to be associated with MDPV.

**TABLE 2**

Examples of self-reported duration of effects of MDPV per route of administration (tentative) as reported by Erowid (2013c). No information on the doses that were used was provided.

<table>
<thead>
<tr>
<th>Duration of effects for MDPV</th>
<th>Oral</th>
<th>Insufflated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total duration</td>
<td>2.0–7.0 hrs</td>
<td>2.0–3.5 hrs</td>
</tr>
<tr>
<td>Onset</td>
<td>15–30 mins</td>
<td>5–20 mins</td>
</tr>
<tr>
<td>Coming Up</td>
<td>30–60 mins</td>
<td>15–30 mins</td>
</tr>
<tr>
<td>Plateau</td>
<td>30–180 mins</td>
<td>30–100 mins</td>
</tr>
<tr>
<td>Coming down</td>
<td>30–120 mins</td>
<td>30–60 mins</td>
</tr>
<tr>
<td>After effects</td>
<td>2–48 hours</td>
<td>1–7 days</td>
</tr>
<tr>
<td>Hangover/day after</td>
<td>?</td>
<td>?</td>
</tr>
</tbody>
</table>

**TABLE 3**

Examples of subjective effects of MDPV as reported by Erowid (2013a). No information on the doses that were used was provided.

<table>
<thead>
<tr>
<th>Subjective effects of MDPV</th>
<th>Positive</th>
<th>Neutral</th>
<th>Negative</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Stimulation (mental and physical)</td>
<td>Stimulation (mental and physical)</td>
<td>(Likelihood of negative side effects increases with higher doses)</td>
</tr>
<tr>
<td></td>
<td>Euphoria, mood lift</td>
<td>Mild elevation in heart rate</td>
<td>Tightened jaw muscles, grinding teeth (trismus and bruxia)</td>
</tr>
<tr>
<td></td>
<td>Increased sociability/talkativeness</td>
<td></td>
<td>Reduced enjoyment of eating/loss of appetite</td>
</tr>
<tr>
<td></td>
<td>Increased productivity and motivation</td>
<td></td>
<td>Disturbed sleep patterns</td>
</tr>
<tr>
<td></td>
<td>Increased mental clarity</td>
<td></td>
<td>Involuntary body movements (twitching, lip-smacking, etc.)</td>
</tr>
<tr>
<td></td>
<td>Enhanced creativity</td>
<td></td>
<td>Confusion and/or scrambled thoughts</td>
</tr>
<tr>
<td></td>
<td>Feelings of empathy</td>
<td></td>
<td>Gastrointestinal disturbance</td>
</tr>
<tr>
<td></td>
<td>Sexual arousal</td>
<td></td>
<td>Muscle tension</td>
</tr>
<tr>
<td></td>
<td>Residual depressed mood</td>
<td></td>
<td>Residual depressed mood</td>
</tr>
<tr>
<td></td>
<td>Nystagmus/eye spasm</td>
<td></td>
<td>Nystagmus/eye spasm</td>
</tr>
<tr>
<td></td>
<td>Anxiousness/nervousness/paranoia</td>
<td></td>
<td>Anxiousness/nervousness/paranoia</td>
</tr>
<tr>
<td></td>
<td>Harsh comedown effects</td>
<td></td>
<td>Harsh comedown effects</td>
</tr>
<tr>
<td></td>
<td>Fiending (re-dosing repeatedly without planning to do so)</td>
<td></td>
<td>Fiending (re-dosing repeatedly without planning to do so)</td>
</tr>
<tr>
<td></td>
<td>Excessive excitation/hyperactivity</td>
<td></td>
<td>Excessive excitation/hyperactivity</td>
</tr>
<tr>
<td></td>
<td>Headache</td>
<td></td>
<td>Headache</td>
</tr>
<tr>
<td></td>
<td>Very elevated heart rate</td>
<td></td>
<td>Very elevated heart rate</td>
</tr>
<tr>
<td></td>
<td>Hallucinations/psychotic behaviour (at high doses or with repeated use)</td>
<td></td>
<td>Hallucinations/psychotic behaviour (at high doses or with repeated use)</td>
</tr>
</tbody>
</table>

**Availability, supply, price**

A search of google.com using the search string ‘buy “MDPV”’ conducted by the EMCDDA in December 2013 for the Joint Report identified a number of online shops offering MDPV for sale in both retail and wholesale quantities. In the former case, MDPV may be sold as a ‘research chemical’.

Data from the National Drug and Alcohol Research Centre’s deep web monitoring programme of the Silk Road marketplace (22,23) (Van Buskirk et al., 2013) identified seven retailers in early February 2013 offering MDPV for sale. Details of the specific quantities and prices were not provided. The number of such retailers was relatively stable over the preceding four months of monitoring (24). It is important to note that the study was conducted before Silk Road was seized and taken offline in October 2013 by the United States Federal Bureau of Investigation. No studies were identified that have examined the sale of MDPV since Silk Road has reopened.

Seizure data and information from collected samples reported by the Member States suggest that MDPV is sold as a drug in its own right and directly on the illicit drug market as cocaine, amphetamine, MDMA and mephedrone.

**3.5. Information on whether or not the new substance is currently under assessment, or has been under assessment, by the UN system — Article 5.2(e) of the Decision**

The World Health Organization is the specialised United Nations agency designated for the evaluation of the medical, scientific and public health aspects of psychoactive substances under the Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 1971. On 10 October 2013, the World Health Organization informed the EMCDDA that MDPV is currently under assessment and the ‘critical review report will be published only early next year (probably April)’.

(22) The National Drug and Alcohol Research Centre (NDARC) is based at the University of New South Wales, Sydney, Australia.

(23) Silk Road is an anonymous, international online marketplace that operates as a Tor hidden service. It uses the peer-to-peer payment network and digital currency Bitcoin for monetary transactions. The original Silk Road marketplace was seized and taken offline on 2 October 2013 by the United States Federal Bureau of Investigation. Since then a new version of Silk Road, sometimes described as ‘Silk Road 2.0’, has become operational. See Christin (2012) for an overview of the original Silk Road.

(24) Nine retailers were identified in late October 2012; 10 in mid-November 2012; 10 in late November 2012; 10 in mid-December 2012; nine in early January 2013; and nine in mid-January 2013. See Christin (2012) for a discussion of some of the market characteristics and dynamics of the original Silk Road.
Article 7.1 of Council Decision states that ‘no risk assessment shall be carried out in the absence of a Europol/EMCDDA Joint Report. Nor shall a risk assessment be carried out where the new psychoactive substance concerned is at an advanced stage of assessment within the United Nations system, namely once the WHO expert committee on drug dependence has published its critical review together with a written recommendation, except where there is significant new information that is relevant in the framework of this Decision’.

The Joint Report has been produced on the understanding that MDPV is not at an advanced stage of assessment within the United Nations system.

3.6. The date of notification on the Reporting Form of the new psychoactive substance to the EMCDDA or to Europol — Article 5.2(f) of the Decision

The first official EMCDDA–Europol notification of MDPV dates from December 2008 from the Finnish National Focal Point. The Reporting Form details a seizure of two quantities of white powder (each of 1 g) intercepted by customs authorities on 24 November 2008 in incoming mail. The powders were in packages marked ‘1-(3,4-methylenedioxyphenyl)-2-pyrrolidinyl-pentan-1-one, purity 99 +%, 1g’. Identification was based on the analytical technique of GC-MS (25).

MDPV was added to the list of new psychoactive substances monitored by the EMCDDA and Europol through the European Union early-warning system and a profile of the substance was created in the EMCDDA European Database on New Drugs (EDND). Since then, analytical details, background information and information relevant to public health have been exchanged between EMCDDA, Europol and the Member States on an ad hoc basis. The Commission and the EMA were kept duly informed.

3.7. Information on whether or not the new psychoactive substance is already subject to control measures at national level in a Member State — Article 5.2(g) of the Decision

Twenty Member States (Belgium, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, France, Germany, Hungary, Ireland, Finland, Italy, Latvia, Luxembourg, Poland, Slovakia, Slovenia, Sweden, and the United Kingdom), as well as Turkey and Norway control MDPV under drug control legislation.

In Belgium it was added to the list of substances on 20 March 2013. In Bulgaria it has been controlled under the Narcotic Substances Control Law since February 2011. In Croatia it is included in the list of drugs, psychotropic substances, plants used to produce drugs and substances that can be used in the production of drugs. In Cyprus it is controlled under the Narcotic Drugs and Psychotropic Substances Law of 1977 as a class B drug that is covered by the generic definition of cathinones. In the Czech Republic it has been included in the Act 167/1998 Coll. on Addictive Substances. In Denmark it is covered by the Executive Order on Euphoriant Substances. In Estonia it has been listed in the Regulation No.73 of the Minister of Social Affairs since 29 November 2010. In Finland it has been listed in the Narcotics Act 373 of 2008 since 28 June 2010. In France it was added to the controlled narcotic substance list since 2 August 2012. In Germany it has been included in the list covered by the Narcotic Substance Law since 26 July 2012. In Hungary it is listed in Schedule A (psychotropic substances) of Act XXV of 1998 on human pharmaceuticals. In Ireland it has been covered by the Misuse of Drugs Acts since 11 May 2010. In Italy it has been controlled generically, as it is a derivative of 2-amino-1-phenyl-1-propanone, under the Decree of the President of the Republic 309/90 since 29 December 2011. In Latvia it is controlled according to Cabinet Regulation 847 ‘Regulations regarding narcotic substances, psychotropic substances and precursors to be controlled in Latvia’. In Luxembourg it has been controlled by the drug control legislation since 30 July 2012. In Poland it is covered by the Act of 15 April 2011 amending the Act of Counteracting Drug Addiction. In Slovakia it is in the first schedule of psychotropic substances set by the Act. No 139/1998 Coll. as amended by the Act. No 43/2011 Coll., which came into force on 1 March 2011. In Slovenia it was included by the Decree on amending the Decree on Classification of Illicit Drugs, Official Gazette of RS No. 62/2013. In Sweden it comes under the Narcotic Drugs Control Act (SFS 1992-860) and the Narcotic Drugs Control Ordinance (SFS 1994-1554). In the United Kingdom it was included in the generic definition of substituted cathinone derivatives placed under the Misuse of Drugs Act 1971 in April 2010. In Turkey it is listed in the Law on Control of Narcotics no.2313. In Norway it has been included by generic scheduling since 14 February 2013.

Three Member States (Austria, Portugal and Romania) control MDPV under legislation penalising unauthorised supply of defined or qualifying new psychoactive substances. In Austria it is controlled under the generic definition within the New Psychoactive Substances Act. In Portugal it is listed as controlled under Decree-Law 54/2013. In Romania, Law 194/2011 subjects to control any psychoactive substance that qualifies by conforming to certain criteria (all substances with psychoactive potential are subject to control until proven harmless by a special designated commission).
In the Netherlands, MDPV sold in consumer amounts is treated as being a medicinal product and must comply with medicines legislation (and general product safety legislation).

Greece, Lithuania and Malta have reported that MDPV is not subject to control measures at the national level.

No information was provided regarding the control status of MDPV in Spain.

3.8. Further information — Article 5.2(h) of the Decision

3.8.1. The chemical precursors that are known to have been used for the manufacture of the substance

No information was reported by the Member States, Turkey or Norway about the chemical precursors or manufacturing methods used to make MDPV. Methods for the production of MDPV are documented in the scientific literature.

3.8.2. The mode and scope of the established or expected use of the new substance

MDPV has been marketed and sold through online shops as a branded ‘legal high’ product and as a ‘research chemical’. MDPV was not declared as an ingredient of the products. This has been confirmed by Denmark, Slovakia and the United Kingdom, each of which reported finding MDPV in samples of branded ‘legal high’ products purchased from the Internet. Furthermore, both Ireland and Poland reported significant numbers of branded ‘legal high’ products collected from bricks and mortar shops (Kelleher et al., 2011). It is also important to note that information from the Member States (such as seizures, collected samples and non-fatal intoxications) and also from user websites suggests that MDPV may be commonly sold as a ‘legal’ replacement for cocaine, amphetamine or MDMA. It is also sold directly on the illicit drug market as these drugs. The use of MDPV by injecting drug users has also been noted (see below). As a result, the mode and scope of use of MDPV may, in part, overlap and/or reflect the mode and scope of use of other stimulants used in recreational settings and by problematic drug users, including those who inject. Additional research is required in order to examine to what extent, if any, the mode and scope of MDPV use overlaps with and/or reflects those groups.

Settings of use

One of the reports of deaths provided by Poland noted the use of MDPV in the context of recreational use (at a party). Samples have been collected from dance venues in Austria and the Netherlands, where it was reported to have been sold as mephedrone, cocaine, MDPV and speed (Austria), and cocaine, synthetic cocaine, ‘moji’, 6-APB, 5-APB, MDPV and ‘meferon’ (the Netherlands). France reported that MDPV was ‘generally used at home during sexual context’ (not further described). Sweden reported that ‘MDPV was popular two years ago among stimulant users, age group 20–30 years; they used MDPV at parties or at home (private parties that lasted from Friday night [until] Sunday night) and at times not regularly; at the moment MDPV is not present, the users stopped using it because of negative side effects, mostly depression and strong craving.’

Price

Six countries reported the price of MDPV. France reported that MDPV was sold at between EUR 2–15 per gram. Hungary reported a price of EUR 13.5 (quantity not specified). Italy reported that prices were from EUR 14.95 for 0.5 g to EUR 169 for 10 g (source: www.spicestore247.biz/mdpv-1). The Netherlands reported information from a forum discussion that included prices for MDPV of EUR 35 per gram and EUR 160 for 5 g. Romania reported a price of EUR 25 (quantity not specified). Spain reported that when MDPV was sold as cocaine the price was EUR 50–60 per gram and when it was sold as MDPV the price was EUR 20 per gram. In 2011 the EMCDDA conducted a study of Internet sites selling new psychoactive substances (EMCDDA, 2012). MDPV was found to be on sale in January 2011 and July 2011 in 25 and 32 shops respectively and the price was reported to be EUR 115–239 for 10 g.

3.8.3. Other use of the new psychoactive substance and the extent of such use, the risks associated with this use of the new psychoactive substance, including the health and social risks

No information was provided by any Member State, Turkey or Norway that indicated that MDPV had any other use apart from legitimate scientific research and as an analytical reference standard.

(26) Other NPS and adulterants such as caffeine and lidocaine have been found in samples.
From the available information it does not appear that MDPV is used in the manufacture of a medicinal product in the European Union. However, the collection of information cannot be considered exhaustive in the absence of a European Union database on the synthetic routes of all medicinal products (27).

4. Information from the EMA as requested by Article 5.3 of the Decision

4.1. Marketing authorisation

The 25 Member States, Norway and Iceland responded to the EMA’s information request (see section 2) reported that the new psychoactive substance MDPV has not obtained a marketing authorisation (28). The EMA also reported that the new psychoactive substance MDPV has not obtained a marketing authorisation through the central authorisation procedure.

4.2. Application for a marketing authorisation

Twenty-five Member States, Norway and Iceland responded to the EMA’s information request (see section 2) reported that the new psychoactive substance MDPV is not the subject of an application for a marketing authorisation (28). The EMA also reported that the new psychoactive substance MDPV is not the subject of an application for a marketing authorisation through the central authorisation procedure.

4.3. Suspended marketing authorisation

Twenty-five Member States, Norway and Iceland responded to the EMA’s information request (see section 2) reported that there had been no cases of a suspended marketing authorisation that had been granted in respect of the new psychoactive substance MDPV (28). The EMA also reported that the new psychoactive substance MDPV is not the subject of a suspended marketing authorisation through the central authorisation procedure.

5. Conclusions

MDPV is a synthetic cathinone derivative, which is closely related to pyrovalerone. MDPV has been present in the EU drug market since at least November 2008 and has been detected in up to 107 non-fatal intoxications and 99 deaths, particularly in Finland and the United Kingdom. There are some indications that it has been sold as a ‘legal’ or synthetic version of cocaine and it has also been found in tablets resembling ‘ecstasy’. Large seizures have been made at borders and police operations have targeted its supply. Powder seizures have been reported, including multi-kilogram quantities. Most, but not all the Member States have control measures at the national level that cover MDPV, however, it continues to be available and this is concerning. We conclude that the health and social risks caused by the manufacture, trafficking and use of MDPV, and in particular the involvement of organised crime and possible consequences of EU-level control measures, could be thoroughly assessed through a risk assessment procedure in accordance with Article 6 of Council Decision 2005/387/JHA.

(27) I.e. products that have been granted a marketing authorisation, or where an application for a marketing authorisation has been made, or where the marketing authorisation has been suspended.

(28) Austria, Belgium, Croatia, the Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, Iceland, Ireland, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden and the United Kingdom provided responses in relation to both human and veterinary medicinal products. Cyprus, Italy, Lithuania, Malta, Romania and Slovakia provided responses in relation to human medicinal products. France, Latvia and Poland provided responses in relation to veterinary medicinal products. In addition, the EMA provided information in relation to both human and veterinary medicinal products in respect of the central authorisation procedure.
References


# Annex 1
Images of MDPV from seizures and collected samples

<table>
<thead>
<tr>
<th>Country</th>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
</table>
| Belgium | ![Image](Belgium.png) | Seizure: November 2010  
40.35 g white powder divided over 74 small bags, seized in Brussels.  
Seizing authority: police |
| Germany | ![Image](Germany.png) | Seizure: September 2010  
1 kg of a white powder, seized in Feucht.  
Seizing authority: police |
| Hungary | ![Image](Hungary.png) | Seizure: July 2009  
300 yellow tablets, seized in Budapest.  
Seizing authority: police |
| Hungary | ![Image](Hungary.png) | Seizure: April 2011  
2 white tablets, seized in Pest county.  
Contents: MDPV and 4-FMC.  
Seizing authority: police |
| Ireland | ![Image](Ireland.png) | Collected sample, analysed in March 2010  
<table>
<thead>
<tr>
<th>Country</th>
<th>Image</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Italy</strong></td>
<td><img src="image1.png" alt="Image" /></td>
<td><strong>Seizures: 2011</strong>&lt;br&gt;Numerous seized samples (powders, agglomerated powders, tablets), seized in Treviso.&lt;br&gt;Contents: MDPV, 4-FA, cocaine and lidocaine or procaine.&lt;br&gt;Seizing authority: Police Department, Treviso</td>
</tr>
<tr>
<td><strong>Malta</strong></td>
<td><img src="image2.png" alt="Image" /></td>
<td><strong>Seizure: March 2011</strong>&lt;br&gt;30 packets containing white powder — 15 g in all. Seized in Attard (EUR 13.5 per gram).&lt;br&gt;Seizing authority: Police Drug Squad</td>
</tr>
<tr>
<td><strong>Slovakia</strong></td>
<td><img src="image3.png" alt="Image" /></td>
<td><strong>Collected sample, analysed in March 2010</strong>&lt;br&gt;310 mg deep blue powder, colourless capsule.&lt;br&gt;Contents: MDPV and mephedrone not quantified.&lt;br&gt;Collecting authority: National Drug Service of Bureau of Fight Against Organised Crime, Police Force Headquarters; analysis was completed by Institute of the Forensic Science of Police Force (IFS).</td>
</tr>
<tr>
<td><strong>Slovakia</strong></td>
<td><img src="image4.png" alt="Image" /></td>
<td><strong>Collected sample, analysed in September 2010</strong>&lt;br&gt;310 mg white powder, colourless capsule.&lt;br&gt;Contents: MDPV and Butylone not quantified.&lt;br&gt;Collecting authority: National Drug Service of Bureau of Fight Against Organised Crime, Police Force Headquarters; analysis was completed by Institute of the Forensic Science of Police Force (IFS).</td>
</tr>
</tbody>
</table>
## Non-fatal intoxications and deaths where MDPV has been analytically confirmed in biological samples

<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Sample type</th>
<th>MDPV result</th>
<th>Results for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Amphetamines (+)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(M, 34)</td>
<td></td>
<td></td>
<td>Amphetamines (+)</td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>Date not specified</td>
<td>Not specified</td>
<td>+</td>
<td>Pyrovalerone (+)</td>
<td>Symptoms included delirium syndrome, hallucination, rhabdomyolysis, tachycardia, hypotension, agitation, logorrhoea, acute renal failure. Man brought in to the emergency department by the police.</td>
</tr>
<tr>
<td>France</td>
<td>Date not specified</td>
<td>Blood</td>
<td>+</td>
<td>Methylene (4400 ng/mL)</td>
<td>Symptoms included tachycardia, mydriasis, hyperton, agitation, profuse sweating, trembling, scariﬁcation, rhabdomyolysis. Paranoid psychosis, aggressivity. Route of administration: inhaled and oral. 10 g. Bought on the Internet. In combination with methylone. Forced hospitalisation.</td>
</tr>
<tr>
<td>France</td>
<td>Date not specified</td>
<td>Hair</td>
<td>+</td>
<td>Alcohol (+)</td>
<td>Intra nasal ingestion. Duration of action: 2 days. Symptoms: mydriasis, paranoid psychosis.</td>
</tr>
<tr>
<td></td>
<td>(M, 22)</td>
<td></td>
<td></td>
<td>Cannabis (+)</td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>Aug 2011</td>
<td>Urine</td>
<td>14 mg/L</td>
<td>Butylone (+)</td>
<td>On admission, the patient was very agitated with tachycardia (Fc 115 bpm). He reported having consumed cannabis, alcohol and 3 white capsules. He was treated with benzodiazepine and discharged 2 days later.</td>
</tr>
<tr>
<td></td>
<td>(M, 20)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>Oct 2012</td>
<td>Blood</td>
<td>12 mg/L</td>
<td>Urine: Ketamine (-) Atoine (-) Scopolamine (-) Levamisole (-) Mephedrone (-) Butylone (-) 4-methylcathinone (-) Methoxetamine (-) APB (29) isomers (-) 4-fluoroamphetamine (-) MDAI (30) (-)</td>
<td>The patient was admitted to the emergency department and reported having consumed (sniffing) ecstasy and synthetic drugs generally named as ‘mefre, crystal and energy’. Symptoms included agitation, mild tachycardia (Fc 105 bpm), distress, psychotic symptoms and visual and auditory hallucinations. During the first 24 hours the patient was treated with fluids, benzodiazepine and haloperidol and was transferred to a psychiatric ward.</td>
</tr>
<tr>
<td></td>
<td>(M, 38)</td>
<td>Urine</td>
<td>17 mg/L</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(29) (Aminopropyl)benzofuran.  
(30) 3,4-methylenedioxyaminonidine.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Sample type</th>
<th>MDPV result</th>
<th>Results for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Italy</td>
<td>Oct 2012 (M, 27)</td>
<td>Urine</td>
<td>On admission: = 55 µg/L 3 days after admission: 35 µg/L</td>
<td>On admission: Alprazolam (113.79 µg/L) Hydroxyalprazolam (103.59 µg/L) 3 days after admission: Chlordiazepoxide (13.03 µg/L) Nordiazepam (81.55 µg/L) Oxazepam (114.99 µg/L) Diazepam (1.26 µg/L) Temazepam (169.90 µg/L) Alprazolam (10.43 µg/L) Alpha-hydroxyalprazolam (13.45 µg/L)</td>
<td>On arrival in the emergency department the patient reported having consumed 3,4-methylenedioxypyrovalerone (MDPV) intravenously for the last 3–4 days, together with benzodiazepine, to counteract the excitatory effect of MDPV. Symptoms included psychomotor agitation, confusion and anxiety. Anamnestic information from the patient revealed previous use of pentedrone and 3-methylmethcathinone abandoned due to decreased interest on these substances. Three days after admission, the patient had a second urine analyses, and reported having continued his use of MDPV. MDPV was purchased via the Internet and marketed as ‘bath salt’.</td>
</tr>
<tr>
<td>Sweden</td>
<td>Jan–Sep 2012</td>
<td>Blood, Urine</td>
<td>+</td>
<td>Result for other substances was positive for 15/17 cases with severe symptoms. Benzodiazepines (7) were the most frequently identified substances. Medicines included buprenorphine, tramadol and fentanyl.</td>
<td>From a total of 86 cases, in 17 cases the symptoms were severe (Poisoning Severity Score — PSS 3) and consisted of extreme agitation, psychosis, hyperthermia, tachycardia, hypertension, myocardial infarction, rhabdomyolysis and renal failure. A few patients needed therapy with sedatives for several days due to prolonged symptoms. See Backberg et al. (2013) for further details.</td>
</tr>
<tr>
<td>Sweden</td>
<td>Apr–May 2012</td>
<td>Not specified</td>
<td>+</td>
<td>None reported</td>
<td>Twelve of the 13 cases described were classified as chronic drug users, with &gt;60 % noted to be HCV positive. See Lindeman et al. (2013) for further details.</td>
</tr>
</tbody>
</table>
## Deaths

<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>Jan 2012</td>
<td>Not specified</td>
<td>+</td>
<td>Butylone (+) Methyline (+) 4-methylcathinone (+) Cocaine (+)</td>
<td>Butylone (bk-MBDB) overdose in combination with methylene, 4-methylcathinone and cocaine.</td>
</tr>
<tr>
<td>Finland*</td>
<td>Sep 2009</td>
<td>Urine Blood</td>
<td>+ (urine)</td>
<td>Blood: Olanzapine (0.7 mg/L) Methadone (0.4 mg/L) Chlorprothixen (0.1 mg/L) Diazepam (0.03 mg/L) Amphetamine (8.4 mg/L)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>Finland</td>
<td>Sep 2009</td>
<td>Blood</td>
<td></td>
<td>40 mg/mL Ethanol (1.5 g/kg) Buprenorphine (0.001 mg/L)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>Finland</td>
<td>Oct 2009</td>
<td>Blood</td>
<td>+</td>
<td>Diazepam (0.1 mg/L) Temazepam (0.3 mg/L) Morphone (0.6 mg/L) Amphetamine (0.88 mg/L) THC (31) (&lt;LOQ)</td>
<td>Accidental death, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td>Finland</td>
<td>Oct 2009</td>
<td>Urine Blood</td>
<td>+ (urine)</td>
<td>Blood: Alprazolam (0.1 mg/L) Tramadol (1.4 mg/L) Methadone (0.2 mg/L) Diazepam (0.02 mg/L)</td>
<td>Accidental death, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td>Finland</td>
<td>Oct 2009</td>
<td>Blood</td>
<td></td>
<td>840 mg/mL (estimated value) Levomepromazine (2.4 mg/L) Trimipramine (0.3 mg/L) Oxycodone (2.2 mg/L)</td>
<td>Suicide, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td>Finland</td>
<td>Oct 2009</td>
<td>Urine Blood</td>
<td>+ (urine)</td>
<td>Blood: Zolpidem (0.4 mg/L) Citalopram (0.9 mg/L) Oxazepam (1.7 mg/L) Olanzapine (0.2 mg/L) Propranolol (2.1 mg/L)</td>
<td>Suicide, propranolol poisoning .</td>
</tr>
<tr>
<td>Finland</td>
<td>Feb 2010</td>
<td>Blood</td>
<td></td>
<td>4 800 mg/mL Blood: Morphone (0.08 mg/L) Amphetamine (1.6 mg/L)</td>
<td>Homicide, multiple injuries to neck.</td>
</tr>
<tr>
<td>Finland</td>
<td>Feb 2010</td>
<td>Urine</td>
<td>+</td>
<td>Temazepam (0.9 mg/L) Diazepam (0.4 mg/L) Amphetamine (7.3 mg/L)</td>
<td>Suicide, hanging.</td>
</tr>
</tbody>
</table>

(31) D9-tetrahydrocannabinol, the main psychoactive substance in cannabis.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>Finland</td>
<td>Feb 2010</td>
<td>Blood</td>
<td>1,800 mg/mL</td>
<td>Methadone (1.3 mg/L)             Temazepam (0.3 mg/L)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diazepam (0.1 mg/L)            Amphetamine (0.06 mg/L) Buprenorphine (0.0044 mg/L)</td>
</tr>
<tr>
<td>11</td>
<td>Finland</td>
<td>Feb 2010</td>
<td>Urine + (urine)</td>
<td>Blood: Tramadol (5.3 mg/L) Valproate (19 mg/L) THC (32) (0.0061 mg/L)</td>
<td>Accidental death, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td>12</td>
<td>Finland</td>
<td>Feb 2010</td>
<td>Blood</td>
<td>70 mg/mL</td>
<td>Ethanol (0.22 g/kg) Amphetamine (0.16 mg/L)</td>
</tr>
<tr>
<td>13</td>
<td>Finland</td>
<td>Feb 2010</td>
<td>Blood</td>
<td>+</td>
<td>Metoclopramide (0.3 mg/L) Diazepam (0.1 mg/L) Oxycodone (0.13 mg/L)</td>
</tr>
<tr>
<td>14</td>
<td>Finland</td>
<td>Feb 2010</td>
<td>Blood</td>
<td>+</td>
<td>None reported</td>
</tr>
<tr>
<td>15</td>
<td>Finland</td>
<td>Mar 2010</td>
<td>Blood</td>
<td>1,200 mg/mL</td>
<td>Ethanol (1.3 g/kg) Venlafaxine (8.7 mg/l) Levomepromazine (0.4 mg/l) Mirtazapine (0.3 mg/l) Nordiazepam (0.05 mg/l) Codeine (0.53 mg/l) Buprenorphine (0.0032 mg/l)</td>
</tr>
<tr>
<td>16</td>
<td>Finland</td>
<td>Mar 2010</td>
<td>Blood</td>
<td>+</td>
<td>Ethanol (0.36 g/kg) Venlafaxine (0.9 mg/l) Alprazolam (0.05 mg/l) Diazepam (0.34 mg/l) Buprenorphine (0.0076 mg/l)</td>
</tr>
<tr>
<td>17</td>
<td>Finland</td>
<td>Apr 2010</td>
<td>Blood</td>
<td>60 mg/mL</td>
<td>Oxazepam (0.46 mg/L) Temazepam (0.006 mg/L) Nordiazepam (0.024 mg/L) Amphetamine (0.11 mg/L) Buprenorphine (0.70 mg/L)</td>
</tr>
<tr>
<td>18</td>
<td>Finland</td>
<td>Jun 2010</td>
<td>Liver Muscle + (liver)</td>
<td>Muscle: Ethanol (0.51 g/kg)</td>
<td>Suicide, hanging.</td>
</tr>
</tbody>
</table>

D9-tetrahydrocannabinol, the main psychoactive substance in cannabis.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>Finland</td>
<td>Jun 2010</td>
<td>Blood</td>
<td>40 mg/mL</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nordiazepam (0.12 mg/L) Morphin (0.15 mg/L) Codeine (0.02 mg/L) Amphetamine (0.20 mg/L) Oxycodone (&lt;LOQ) THC (+) (+)</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Finland</td>
<td>Sep 2010</td>
<td>Blood</td>
<td>20 mg/mL</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Methadone (0.3 mg/L) Temazepam (0.13 mg/L) Oxazepam (0.15 mg/L) Nordiazepam (0.026 mg/L) Amphetamine (+)</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Finland</td>
<td>Oct 2010</td>
<td>Blood</td>
<td>530 mg/mL</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Diazepam (0.033 mg/L) DPMP (+) (+) Methylone (+)</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Finland</td>
<td>Feb 2011</td>
<td>Hair Blood</td>
<td>+ (hair)</td>
<td>Suicide, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood: Amitriptyline (4.3 mg/L) Hydroxyzine (1.1 mg/L) Citalopram (0.7 mg/L) Perfenazine (0.21 mg/L)</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Finland</td>
<td>Feb 2011</td>
<td>Urine Blood</td>
<td>+ (urine)</td>
<td>Disease, other and unspecified cirrhosis of liver.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Blood: Alprazolam (0.018 mg/L) Methadone (0.4 mg/L) Diazepam (0.13 mg/L)</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Finland</td>
<td>Apr 2011</td>
<td>Blood</td>
<td>+</td>
<td>Suicide, crushing injury of skull.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alprazolam (0.44 mg/L) Cionaxepam (0.12 mg/L) Amphetamine (0.42 mg/L) Buprenorphine (0.00042 mg/L)</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Finland</td>
<td>May 2011</td>
<td>Hair Blood</td>
<td>+ (hair)</td>
<td>Accidental death, poisoning by drugs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Coronary blood: Temazepam (1.1 mg/L) Quetiapine (0.3 mg/L) Methadone (0.2 mg/L) Diazepam (0.029 mg/L)</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>Finland</td>
<td>May 2011</td>
<td>Hair Liver</td>
<td>+ (hair)</td>
<td>Accidental death, poisoning by drugs.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Liver: Temazepam (+) Methadone (+) Quetiapine (+)</td>
<td>This case has a connection to case 25 — the two deceased were found together.</td>
</tr>
<tr>
<td>27</td>
<td>Finland</td>
<td>May 2011</td>
<td>Blood</td>
<td>110 mg/mL</td>
<td>Suicide, toxic effect of carbon monoxide (COHb (35) 71 %).</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nordiazepam (0.20 mg/L)</td>
<td></td>
</tr>
</tbody>
</table>

(33) D9-tetrahydrocannabinol, the main psychoactive substance in cannabis.
(34) (Diphenylmethyl)piperidine.
(35) Carboxyhaemoglobin.
<table>
<thead>
<tr>
<th>No.</th>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Finland</td>
<td>Jun 2011</td>
<td>Urine</td>
<td>+</td>
<td>Diazepam (0.30 mg/L) Buprenorphine (0.0037 mg/L) Alprazolam (+) Clonazepam (+)</td>
<td>Suicide, crushing injuries involving other combinations of body regions.</td>
</tr>
<tr>
<td>29</td>
<td>Finland</td>
<td>Jul 2011</td>
<td>Blood</td>
<td>30 mg/mL</td>
<td>Methadone (0.6 mg/L) Temazepam 0.22 mg/L Diazepam (0.15 mg/L) Buprenorphine (0.0017 mg/L)</td>
<td>Accidental death, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td>30</td>
<td>Finland</td>
<td>Oct 2011</td>
<td>Blood</td>
<td>170 mg/mL</td>
<td>2.3-DMMC (36) (0.01 mg/L) Amphetamine (1.8 mg/L)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>31</td>
<td>Finland</td>
<td>Oct 2011</td>
<td>Blood</td>
<td>190 mg/mL</td>
<td>Methadone (1.1 mg/L) Oxazepam (0.077 mg/L) Amphetamine (0.24 mg/L) Pregabalin (3.7 mg/L)</td>
<td>Accidental death, poisoning by drugs or medicaments.</td>
</tr>
<tr>
<td>32</td>
<td>Finland</td>
<td>Jan 2012</td>
<td>Hair</td>
<td>+</td>
<td>Buprenorphine (+) Verapamil (+) Propofol (+) Diazepam (+)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>33</td>
<td>Finland</td>
<td>Apr 2012</td>
<td>Blood</td>
<td>130 mg/mL</td>
<td>Fentanyl (0.0097 mg/L) Clonazepam (0.005 mg/L)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>34</td>
<td>Finland</td>
<td>Jul 2012</td>
<td>Blood</td>
<td>1,700 mg/mL</td>
<td>Olanzapine (0.3 mg/L) Alprazolam (0.005 mg/L) GHB (37) (1 500 mg/L)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>35</td>
<td>Finland</td>
<td>Jul 2012</td>
<td>Blood</td>
<td>80 mg/mL</td>
<td>Ethanol (0.23 g/kg) Isopropylalcohol (0.1 g/kg) Diazepam (0.048 mg/L) Buprenorphine (0.0079 mg/L)</td>
<td>Accidental death, poisoning by narcotics.</td>
</tr>
<tr>
<td>36</td>
<td>Finland</td>
<td>Jul 2012</td>
<td>Blood Vitreous humour</td>
<td>590 mg/mL (blood)</td>
<td>Blood: α-PVP (38) (0.60 mg/L) Amphetamine (1.6 mg/L) Vitreous humour: Ketamine (+)</td>
<td>Accidental death, multiple fractures of ribs.</td>
</tr>
<tr>
<td>37</td>
<td>Finland</td>
<td>Nov 2012</td>
<td>Urine Blood</td>
<td>+ (urine)</td>
<td>Blood: Diazepam (0.064 mg/L) Buprenorphine (0.00066 mg/L) Pregabalin (4.4 mg/L) Amphetamine (&lt; LOQ)</td>
<td>Disease, intoxication — psychoactive substances.</td>
</tr>
</tbody>
</table>

(36) 2,3-dimethylmethcathinone.  
(37) Gammahydroxybutyrate.  
(38) α-Pyrrolidinovalerophenone.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Finland</td>
<td>Dec 2012</td>
<td>Blood</td>
<td>30 mg/mL</td>
<td>Doxepine (1.5 mg/L) Citalopram (1.9 mg/L) Quetiapine (1.3 mg/L) α-PVP (0.070 mg/L) Buprenorphine (0.029 mg/L) Temazepam (&lt;LOQ)</td>
<td>Suicide, doxepin poisoning.</td>
</tr>
<tr>
<td>Finland</td>
<td>Jan 2013</td>
<td>Urine</td>
<td>+</td>
<td>Ethanol (1.6 g/kg) Alprazolam (0.005 g/l) Diazepam (0.45 g/l) Codeine (0.15 g/l) Buprenorphine (0.0006 g/L)</td>
<td>Cause of death not yet registered.</td>
</tr>
<tr>
<td>Finland</td>
<td>Apr 2013</td>
<td>Blood</td>
<td>30 mg/mL</td>
<td>Trimethoprim (1.6 mg/L)</td>
<td>Cause of death not yet registered.</td>
</tr>
<tr>
<td>Finland</td>
<td>Aug 2013</td>
<td>Urine</td>
<td>+</td>
<td>Alprazolam (0.044 mg/L) Diazepam (0.092 mg/L) TH5 (0.0051 mg/L) Buprenorphine (0.0012 mg/L) Fentanyl (0.0082 mg/L) Pregabalin (4.0 mg/L)</td>
<td>Cause of death not yet registered.</td>
</tr>
<tr>
<td>France</td>
<td>Oct 2012</td>
<td>Blood</td>
<td>106 µg/L (blood) 760 µg/L (urine)</td>
<td>PVP (40 µg/L in blood) 295 µg/L in urine Pentedrone (33 µg/L in blood) 110 µg/L in urine Hydroxyzine (194 µg/L in blood) Nordazepam (47 µg/L in blood) Oxazepam (8 µg/L in blood) Cannabinoic acid (15.7 µg/L in blood) Ethanol (0.3 g/L in blood)</td>
<td>Cause of death: drowning.</td>
</tr>
<tr>
<td>Norway</td>
<td>2012</td>
<td>Blood</td>
<td>+</td>
<td>None reported</td>
<td>Cause of death not reported.</td>
</tr>
<tr>
<td>Poland</td>
<td>Sep 2010</td>
<td>Blood</td>
<td>430 ng/mL</td>
<td>Ephedrine (324 ng/mL)</td>
<td>Cause of death: ‘metabolic dysfunction’ caused by MDPV.</td>
</tr>
<tr>
<td>Poland</td>
<td>2011</td>
<td>Blood</td>
<td>38 ng/mL</td>
<td>Buphedrone (127 ng/mL)</td>
<td>Indirect death: car accident. During inspection of the deceased driver, the police found packages of white powder, labelled ‘Ivory Speed’ and ‘Exclusive Dust’, and a note reading ‘collector’s product for field stone rinsing’. See Adamowicz et al. (2013) for further information.</td>
</tr>
<tr>
<td>Poland</td>
<td>2011</td>
<td>Blood</td>
<td>17 ng/mL</td>
<td>Clonazepam (1.2 ng/mL) 7-aminoconazepam (96 ng/mL)</td>
<td>Death after a night of partying. A witness testified that the man had taken a product called ‘Speedway’. The autopsy showed emaciation, external hydrocephalus and atherosclerosis. Deceased with a history of drug addiction, HIV+. See Adamowicz et al. (2013) for further information.</td>
</tr>
</tbody>
</table>

(TH5) D9-tetrahydrocannabinol, the main psychoactive substance in cannabis.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>47-49</td>
<td>Sweden 2010</td>
<td>Not specified</td>
<td>+</td>
<td>None reported</td>
<td>3 cases. The deaths were intoxications involving several substances (not further described).</td>
</tr>
<tr>
<td>50-52</td>
<td>Sweden 2011</td>
<td>Not specified</td>
<td>+</td>
<td>None reported</td>
<td>3 cases. None of the 3 deaths related only to MDPV.</td>
</tr>
<tr>
<td>53-61</td>
<td>Sweden 2012</td>
<td>Not specified</td>
<td>+</td>
<td>None reported</td>
<td>9 cases. There were several accidents, death by hanging and intoxications with several drugs (not further described).</td>
</tr>
<tr>
<td>62-67</td>
<td>Sweden 2013</td>
<td>Not specified</td>
<td>+</td>
<td>None reported</td>
<td>6 cases. There was one car accident and intoxications with several drugs (not further described).</td>
</tr>
</tbody>
</table>

(40) Methylene-dioxymethamphetamine (commonly known as 'ecstasy').
(41) 3,4-methylene-dioxyaminoindane.
(42) 5-idoaminoindane.
(43) Alpha-methyltryptamine.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>United Kingdom</strong>&lt;sup&gt;<strong>2</strong>&lt;/sup&gt;</td>
<td>Jan–Dec 2012</td>
<td>Blood, Urine</td>
<td>+</td>
<td>None reported</td>
<td>11 cases. 6 cases of hanging. 1 case murder victim. 1 case murder suspect. 2 cases found dead at home. 1 case found in a canal. 1 case found dead in a car (carbon monoxide poisoning). (One of the cases is a duplicate, although it is not certain which one, hence this group is counted as 11 cases — see death 99).</td>
</tr>
<tr>
<td><strong>United Kingdom</strong>&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Jan 2010</td>
<td>Blood</td>
<td>0.01 mg/L</td>
<td>N-desalkyl-4-methylmethcathinone (+)</td>
<td>Coronary artery disease in the presence of MDPV. Coroner’s verdict: open verdict/unascertained.</td>
</tr>
<tr>
<td><strong>United Kingdom</strong>&lt;sup&gt;6&lt;/sup&gt;</td>
<td>Feb 2010</td>
<td>Blood, Gastric</td>
<td>+ (blood)</td>
<td>Fentanyl (+)  C24 ng/mL in blood)  (37 µg in gastric sample)  Cannabis (+)</td>
<td>Fentanyl toxicity implicated. Coroner’s verdict: open verdict/unascertained.</td>
</tr>
<tr>
<td><strong>United Kingdom</strong>&lt;sup&gt;9&lt;/sup&gt;</td>
<td>Nov 2010</td>
<td>Blood, Urine</td>
<td>&lt;LOD (blood) + (urine)</td>
<td>Alcohol (+)  Mephedrone (+)  levamisole (+ in urine)  quinine (+ in urine)</td>
<td>Multiple injuries. Had taken a variety of substances and alcohol. Coroner’s verdict: suicide. Implicated drugs alcohol, mephedrone and MDPV.</td>
</tr>
</tbody>
</table>

<sup>2</sup> D9-tetrahydrocannabinolic acid, a breakdown product of D9-tetrahydrocannabinol, the main psychoactive substance in cannabis.

<sup>4</sup> Gammabutyrolactone.

<sup>6</sup> Limit of detection — the lowest amount that can be detected by the method used.
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>United Kingdom</td>
<td>Jun 2010</td>
<td>Blood</td>
<td>0.13 µg/L</td>
<td>Alcohol (175 mg/100mL) Citalopram (0.12 mg/L)</td>
<td>Carbon monoxide poisoning, alcoholic liver disease. Implicated: 4-fluoromethcathinone and mephedrone. Coroner’s verdict: suicide.</td>
</tr>
<tr>
<td></td>
<td>(M, 39)</td>
<td></td>
<td></td>
<td>Diazepam (85 µg/L) Temazepam (99 µg/L)</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Apr 2010</td>
<td>Blood</td>
<td>0.11 mg/L</td>
<td>4-fluoromethcathinone (0.21 mg/L in blood)</td>
<td>Asphyxia. Implicated: 4-fluoromethcathinone and mephedrone. Coroner’s verdict: accidental/misadventure.</td>
</tr>
<tr>
<td></td>
<td>(M, 29)</td>
<td>Urine</td>
<td></td>
<td>(23.02 mg/mL in urine) Mephedrone (≤0.05 mg/L in urine) Ibuprofen (+) blood</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Jun 2010</td>
<td>Blood</td>
<td>0.41 mg/L (blood)</td>
<td>Amphetamine (+ blood) Mephedrone (0.05 mg/L in blood)</td>
<td>Cardiac arrest caused by either multiple drug toxicity or excited delirium. Coroner’s verdict: accidental/misadventure.</td>
</tr>
<tr>
<td></td>
<td>(M, 38)</td>
<td>Urine</td>
<td>0.75 mg/L (urine)</td>
<td>Mephedrone (0.05 mg/L in urine) 4-fluoromethcathinone (0.55 mg/L in blood) (6.51 mg/L in urine)</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Jun 2010</td>
<td>Unspecified</td>
<td>1.5 mg/L</td>
<td>Alcohol (57 mg/100mL) Benzodiazepine (74 mg/L) TFMP ** (1.9 mg/L) Lignocaine (+)</td>
<td>Cause of death unascertained. Coroner’s verdict: open verdict/unascertained.</td>
</tr>
<tr>
<td></td>
<td>(M, 33)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Feb 2011</td>
<td>Blood</td>
<td>+ (blood)</td>
<td>Amphetamine (0.04 µg/mL in blood) Lignocaine (+)</td>
<td>Hanging. Coroner’s verdict: open verdict/unascertained.</td>
</tr>
<tr>
<td></td>
<td>(M, 37)</td>
<td>Nasal swab</td>
<td>+ (nasal swab) both low level</td>
<td>Lignocaine (+ on nasal swab) Benzocaine (+ on nasal swab Sertraline (+ in blood) Diazepam (+ in blood)</td>
<td></td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Apr 2011</td>
<td>Blood</td>
<td>1.63 mg/L</td>
<td>MDMA ** (7460 µg/L) Cocaine (929 µg/L) Benzoylecgonine (1.89 mg/L) Mephedrone (0.17 mg/mL) Diazepam (3.284 µg/L) Nordiazepam (1.138 µg/L)</td>
<td>Drowning and multiple drug overdose. Implicated: MDMA, cocaine and mephedrone. Coroner’s verdict: accidental/misadventure.</td>
</tr>
</tbody>
</table>

(**) Trifluoromethylphenylpiperazine.  
(48) Methylenedioxymethylamphetamine (commonly known as ‘ecstasy’).
<table>
<thead>
<tr>
<th>Country</th>
<th>Date</th>
<th>Biological sample</th>
<th>MDPV result</th>
<th>Results of toxicological analysis for other substances</th>
<th>Notes</th>
</tr>
</thead>
</table>
| United Kingdom | May 2011   | Blood, Urine      | +           | MDPBP (49) (1.55 mg/l in blood), (94.2 mg/l in urine)  
Pentylone (0.34 mg/l in blood)  
(29.4 mg/l in urine)  
Mephedrone (+ in matrix unknown)  
Coroner’s verdict accidental/misadventure.                                                                                           |
| United Kingdom | Dec 2011   | Not specified     | +           | MDMA (+)  
Cocaine (+)  
Cathinone (+)                                                                                                            | MDMA, cocaine, MDPV and methylmethcathinone toxicity. Implicated: ecstasy, cocaine and cathinones.  
Coroner’s verdict: open verdict/unascertained.                                                                                      |
| United Kingdom | Aug 2011   | Unspecified       | +           | None reported                                                                                                           | MDPV and heart attack.  
Coroner’s verdict: open verdict/unascertained.                                                                                      |
| United Kingdom** | Apr 2012  | Blood             | <0.1 mg/L   | AMT (50) (0.89 mg/L)                                                                                                   | Cause of death: cardiac failure, MDPV and AMT drug toxicity plus left ventricular hypertrophy and obesity.  
Coroner’s verdict: accidental/misadventure.                                                                                           |

In this table LOD is the limit of detection and LOQ is the limit of quantitation.

* All cases in Finland are from medico-legal source and include suspect and unnatural deaths, non-related to poisoning.

** The United Kingdom reported data on fatal intoxications from two separate sources, ROAR Forensics and the national programme for Substance Abuse Deaths (np-SAD). It should be noted that, based on case-specific details, case 99 is believed to be a duplicate of one of the cases reported in the aggregated data from 2012, and has been counted once only.

(49) 3,4-methylenedioxy-α-pyrrolidinobutyrophenone.
(50) Alpha-methyltryptamine.
Recommended citation:


About the EMCDDA

The European Monitoring Centre for Drugs and Drug Addiction is the hub of drug-related information in Europe. Its mission is to provide the European Union and its Member States with ‘factual, objective, reliable and comparable information’ on drugs and drug addiction and their consequences. Established in 1993, it opened its doors in Lisbon in 1995, and is one of the European Union’s decentralised agencies. The Centre offers policymakers the evidence base they need for drawing up drug laws and strategies. It also helps professionals and researchers pinpoint best practice and new areas for analysis.

Related publications and websites

EMCDDA


EMCDDA and Europol


These and all other EMCDDA publications are available from www.emcdda.europa.eu/publications

Legal notice: The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, the EU Member States or any institution or agency of the European Union. More information on the European Union is available on the Internet (europa.eu).

Luxembourg: Publications Office of the European Union

© European Monitoring Centre for Drugs and Drug Addiction, 2014
Reproduction is authorised provided the source is acknowledged.

This publication is only available in electronic format.

EMCDDA, Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal
Tel. (351) 211 21 02 00 | info@emcdda.europa.eu
emcdda.europa.eu | twitter.com/emcdda | facebook.com/emcdda